Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10447781 | 0.89 | NOTUM (0.78) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL29378534 | 0.79 | MAPT (0.50) | NOTUMMAPTCYP19A1ENPP2MKNK1 | |
| SCHEMBL11102521 | 0.78 | NOTUM (1.00) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL21777006 | 0.78 | NOTUM (1.00) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL3089639 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL76794 | 0.78 | NOTUM (0.64) | NOTUMMAPTCYP19A1KEAP1 | |
| SCHEMBL8117312 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL482167 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL239581 | 0.78 | NOTUM (1.00) | NOTUMMAPTCYP19A1KEAP1 | |
| SCHEMBL3681868 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115755526-A | Photosensitive resin composition and method for producing cured relief pattern | 旭化成株式会社 | 2023-03-07 | — | — | CN | disclosed |
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-20160213618-A1 | COMPOSITIONS OF 5-ETHYL-2--PYRIMIDINE | CYMABAY THERAPEUTICS INC (US) | 2016-07-28 | — | — | US | disclosed |
| US-9241924-B2 | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine | CYMABAY THERAPEUTICS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| CN-101312948-B | Biaryl substituted heterocycle inhibitors of lTA4H for treating inflammation | DECODE GENETICS EHF | 2015-01-14 | — | — | CN | disclosed |
| EP-1926708-B1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2014-06-18 | — | — | EP | disclosed |
| CN-103483317-A | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC | 2014-01-01 | — | — | CN | disclosed |
| EP-2643310-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-103328482-A | New bicyclic compound for modulating G protein-coupled receptors | HANMI PHARM IND CO LTD | 2013-09-25 | — | — | CN | disclosed |
| CN-103298801-A | 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as GPR 119 modulators | PFIZER | 2013-09-11 | — | — | CN | disclosed |
| CN-1925833-A | Keratin dyeing compounds, keratin dyeing compositions containing them, and their use | PROCTER & GAMBLE (US) | 2007-03-07 | — | — | CN | disclosed |
| US-20060116407-A1 | Amide derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006053778-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-26 | — | — | WO | disclosed |
| CN-1184196-C | Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | AVENTIS PHARMA GMBH (DE) | 2005-01-12 | — | — | CN | disclosed |
| US-6703411-B2 | ANTIISCHEMIC AGENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-09 | — | — | US | disclosed |
| CN-1422257-A | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker | EURO CELTIQUE SA (LU) | 2003-06-04 | — | — | CN | disclosed |
| CN-1395558-A | substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | AVENTIS PHARMA GMBH (DE) | 2003-02-05 | — | — | CN | disclosed |
| EP-1259481-A1 | SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND A MEDICAMENT CONTAINING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2002-11-27 | — | — | EP | disclosed |
| US-20010016596-A1 | Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2001-08-23 | — | — | US | disclosed |
| WO-2001053256-A1 | SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND A MEDICAMENT CONTAINING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116407-A1 | Amide derivatives | GLS, SDHA, GLS2 | NOTUM 345/4885MAPT 3340/4885CYP19A1 47/4885 |
| US-20160213618-A1 | COMPOSITIONS OF 5-ETHYL-2--PYRIMIDINE | DPYD, UMPS, TYMS | NOTUM 2972/4885MAPT 1318/4885CYP19A1 2635/4885 |
| US-20010016596-A1 | Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | TNNI3, TNNT2, RYR1 | NOTUM 2759/4885MAPT 4830/4885CYP19A1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.